Allarity Therapeutics Inc (ALLR) News

$ALLR THESE PARTS OF THE LAST PR STAND OUT TO ME. TELLS ME THEY ARE ACTIVELY LOOKING FOR PARTNERS OR BUYOUT. THEY HAVE GOTTEN VERY GOOD RESULTS, SO GOOD THEY STOPPED THE LAST TRIAL EARLY. YOU DON’T DO THAT UNLESS THE PATIENTS HAVE BENIFITTED. FDA COULD COME I AND FAST FRACK THIS. ITS JUST MEANT TO EXTEND LIFE ON ADVANCED OVARIAN CANCER PATIENTS. SOFAR THEY HAVE PROVED IT SHRINKS TUMOR SIZE.
“Not only does the safety profile stand out when compared to chemotherapies, which is often the alternative for this patient group, but the safety metrics are indeed also favorable when compared to first-generation PARP inhibitors. As we see it, stenoparib may represent the next-generation alternative for advanced ovarian cancer patients. Therefore, we are aggressively working with Dr. Moore and other leading experts to design a trial that will help advance and quicken stenoparib’s clinical progress toward registration with the FDA.”

“After conducting a detailed review of the stenoparib monotherapy trial data, including the data announced today, the Company has concluded that these data may be of significant interest among key oncologists, potential commercial partners, and other relevant stakeholders and therefore warrant presentation within a high-level scientific conference. Further release of these clinical data is intended to be staged to comply with the common rules of scientific conferences, which do not allow data to be published before the event.”

The PARP inhibitor market is expected to reach $22 billion in revenue by 2028, and has historically seen significant partnerships and acquisitions.

For example, one significant acquisition included a multi-asset deal potentially totaling $1.5 billion, which featured an advanced PARP inhibitor.

Allarity has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121.

More trash stinking up the markets!! Get this POS delisted and out of here!!

U too my man

Have a great 4th.

I’m thinking the same especially if it’s got the FDA involved

still holding all I still believe this will run. the next trial will really make it fly if its favorable.

Whatcha thinking on what is happening now bro?

Agreed, i loaded today at 20 cents

I think the shorts are giving share holders a gift at these prices, if this passes Phase three ---- look out shorty

Now would be a good time to throw everything and the kitchen sink to stabilize this and kill the short attack

IF the os/float is not increasing than it's nss. everyone is saying dilution. my only issue is why do they dilute at .30- 20 cents when they could do it much higher. maybe the said dilution volume is from the buyer. all imo

Definitely shenanigans
If the RS shorts will attack and bring it down again
They need an alternative. Partnerships joint venture or buyout

buys and sells almost equal. dark pool vol was 60% of total traded today. what the fruk shorts got this one in death grip. but everything is purposeful and deliberate. i am thinking they sell some assets as well to keep them from being banished to the otc.

Yes what I’m hoping for is a buyout from a big firm.
They are only in phase 2, generally the norm is phase 4 before it’s approved

ALLR has a product thats doing well ( i know its a huge gamble at this stage) shorts will have to cover sooner or later.

This shorting shit should be illegal

There’s no bottom to tell, they will keep attacking. They have the threat of delisting and RS unfortunately

I'm watching trying to figure how low it will go, I'm not giving up on it thats for sure.

The dudes short on Twitter are pounding the shit out of it trying to get it lower

We need the fear of a RS and delisting to go away

betting on a bounce here

Unfortunately for us who stayed it’s the only option

Then I'll buy the heck out of it.

Could end up at a Nickel if they get delisted

All true! Shorts, fear and dilution are dropping it

Yes but they could be bought out at any time???

I know but people need to remember they have a product Maybe I'm reading this all wrong IDK

And they are to far away from fda approval to push it up

Pls get me in, what are you guys excited about here?

Unfortunately the fear of delisting is driving the sell off

I added .25 again this is ridiculous

not unreasonable to hope for a bounce here

This is not good, how low will it go????

I just added a few more. sheesh

Just getting punished damn

Multiple patients have now exceeded 30 weeks on treatment
Boston ( June 25 , 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that multiple patients in its Phase 2 clinical trial of stenoparib for advanced recurrent ovarian cancer have been on treatment for more than 30 weeks.
The continued durability of clinical benefit further bolsters the Company’s announcement in early May 2024 that stenoparib had shown clear clinical benefit, including significant tumor shrinkage and long-term disease stability, in patients who had been heavily pre-treated for their ovarian cancer and otherwise have limited life expectancy. These results provided clinical proof of concept for stenoparib as a treatment in this patient population, prompting the company to halt patient enrollment to focus its resources on developing a follow-on trial designed to accelerate the path for stenoparib toward regulatory approval.
Kathleen N. Moore , MD, MS, Deputy Director of the Stephenson Cancer Center , Professor of the Section of Gynecol

Allarity Therapeutics Announces Multiple Patients In Its Phase 2 Stenoparib Trial Have Exceeded 30 Weeks On Treatment

U bet Scottie....

Right on 💰Gdog

Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
Allarity Therapeutics, Inc.
Tue, May 7, 20243 min read

In This Article:
ALLR
-26.91%
Allarity Therapeutics, Inc.Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc.
- Conversions Eliminate All Variable Priced Derivative Securities

- Conversions Eliminate Any Market Overhang from Warrants

- Series A Preferred and Warrant Conversions were Investor Initiated

- Limited Number of Warrants Convertible at $20 Per Share Remain

- Company Has Paid Off All Bridge Notes in Full



Boston (May 7, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that its capital structure has been simplified. This was achieved by the recent investor-initiated conversion of all outstanding Series A Preferred Stock into common stock, resulting in a single class of shares outstanding, and the conversion of 93% of the Company’s outstanding warrants, including all variable-priced warrants. Following this reduction, the Company reports that only a limited number of warrants remain unexercised, specifically 256,667 warrants, each with a fixed exercise price of $20 per share. Furthermore, the Company informs that it has fully paid off all bridge notes, totaling $1,746,630, including principal and accrued interest.

Thomas Jensen, CEO of Allarity Therapeutics, stated, “The successful conversion of these securities by our investors is a key milestone, as it streamlines our financial architecture and may enhance the attractiveness of our stock. Understanding the investment case for biotech companies like ours can be complex for investors at all levels. Therefore, we are very pleased with this development, as it allows us to focus more on sharing information about our lead asset, stenoparib, and less on explaining the intricacies of our capital structure going forward.”

About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.

In my humble opinion the shrts will have to cover sooner or later, this has a promising product and if news comes Katty bar the doors.
Last time i looked the shrt posistion had triple to over 1.4 m shares

Absolute TRASH!!!

Still holding all

News release of fda sanctioned trial should send it soaring imo

My birdie says maybe news will come by next week. So iam holding and adding.my trading style is however aggressive. common sense says you should have already taken the loss..I actually sold a month ago and rebought in last week

ALLR new 52 week low

Is it time to bail on this one or see what happens?

So they meet on Thursday. Then a decision is 6-8 weeks from then? What’s your guess on when the updated results are?

Very possible they do! To forgo their other cancer therapy’s and go balls to the wall on this one tells me they are very confident

they will get 6-8 weeks easily before a decision. why wait ? they have an ace up their sleeves IMO